FC
AKRO

FORA Capital’s Akero Therapeutics AKRO Stock Holding History

FORA Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,473
Closed -$667K – 489
2025
Q1 		$667K Buy
+16,473
New +$698K 0.07% 287
2020
Q2 		– Sell
-4,369
Closed -$93K – 863
2020
Q1 		$93K Buy
+4,369
New +$93.7K 0.02% 627

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FORA Capital's AKRO Position: Q2 2025 in Review

FORA Capital sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 16,473 shares — an estimated $667K sold.

FORA Capital first reported a position in AKRO in Q1 2020 and held it in 2 quarters. The position peaked at $667K in Q1 2025. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • FORA Capital reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • FORA Capital sold 16,473 Akero Therapeutics shares in Q2 2025, an estimated $667K.
  • FORA Capital first reported a position in Akero Therapeutics in Q1 2020 and held it in 2 quarters.
  • FORA Capital's Akero Therapeutics position peaked at $667K in Q1 2025.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on FORA Capital's 13F filing for Q2 2025, filed 13 Aug 2025.